To better understand
the role of dopamine D
4
receptor
(D
4
R) in glioblastoma (GBM), in the present paper, new
ligands endowed with high affinity and selectivity for D
4
R were discovered starting from the brain penetrant and D
4
R selective lead compound 1-(3-(4-phenylpiperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1
H
)-one (
6
). In particular, the D
4
R antagonist
24
, showing the highest affinity and selectivity
over D
2
R and D
3
R within the series (D
2
/D
4
= 8318, D
3
/D
4
= 3715), and the
biased ligand
29
, partially activating D
4
R
G
i
-/G
o
-protein and blocking ÎČ-arrestin
recruitment, emerged as the most interesting compounds. These compounds,
evaluated for their GBM antitumor activity, induced a decreased viability
of GBM cell lines and primary GBM stem cells (GSC#83), with the maximal
efficacy being reached at a concentration of 10 ÎŒM. Interestingly,
the treatment with both compounds
24
and
29
induced an increased effect in reducing the cell viability with
respect to temozolomide, which is the first-choice chemotherapeutic
drug in GBM.